RxDoctor Payments Data

Almos Nagy, MD

Psychiatry · Manchester, NHNPI 1184848467

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 67.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $304 and has fallen 80.7% since, to $59 in 2024.

$648in general payments, 2019–2025

Across 55 payments — averaging $11.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$436
  • Lundbeck LLC$71
  • Sunovion Pharmaceuticals Inc.$50
  • Vanda Pharmaceuticals Inc.$44
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21
  • Corium, LLC$14
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$648 in reported general payments places this provider in the 70th percentile of 166 psychiatry providers in New Hampshire.

See all psychiatry providers in New Hampshire

Medicare billing

Part B allowed, 2024
$24,176
Medicare patients
41
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$15,768
Venlafaxine Hcl ErVenlafaxine Hcl38$2,027
Aripiprazole18$1,817
Fluvoxamine Maleate16$1,799
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine67$1,755
Oxcarbazepine19$1,574
Ziprasidone Hcl14$1,405
Clonazepam88$1,241
Methylphenidate Hcl35$1,135
Bupropion XlBupropion Hcl34$957
Quetiapine Fumarate21$875
Mirtazapine40$635
Escitalopram Oxalate22$633
Trazodone Hcl61$631
Sertraline Hcl56$599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$436$15,76812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 166 psychiatry providers in New Hampshire.

Other psychiatry in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →